SCHEMBL28715917

SCHEMBL28715917

CC(C)N(NC(=O)OCc1ccccc1)C(=O)OC(C)(C)C

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.53
SYK P43405 1/20 0.51
LMNA P02545 1/20 0.48
AKT1 P31749 2/20 0.47
CTSK P43235 3/20 0.45
ATM Q13315 1/20 0.44
CA12 O43570 3/20 0.44
CA1 P00915 3/20 0.44
CA2 P00918 2/20 0.44
CA9 Q16790 2/20 0.44
BACE1 P56817 2/20 0.43
CTSS P25774 2/20 0.43
CA7 P43166 1/20 0.43
CA14 Q9ULX7 1/20 0.43
CTSL P07711 1/20 0.43
CTSB P07858 1/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
MAPT P10636 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18343680 0.90 SMN1; SMN2 (0.51) SMN1; SMN2SYKLMNAAKT1CTSK
SCHEMBL4152470 0.83 SMN1; SMN2 (0.56) SMN1; SMN2SYKLMNAAKT1CTSK
SCHEMBL25002520 0.81 SYK (0.53) SMN1; SMN2SYKLMNAAKT1CTSK
SCHEMBL3722611 0.78 SYK (0.50) SMN1; SMN2SYKLMNAAKT1
SCHEMBL29838906 0.77 SMN1; SMN2 (0.50) SMN1; SMN2LMNACTSKATMCTSS
SCHEMBL13269432 0.77 SMN1; SMN2 (0.56) SMN1; SMN2SYKLMNAAKT1CA12
SCHEMBL6352709 0.77 AKT1 (0.48) SMN1; SMN2SYKLMNAAKT1CTSK
SCHEMBL4148951 0.77 SMN1; SMN2 (0.50) SMN1; SMN2SYKLMNAAKT1CTSK
SCHEMBL4679985 0.76 SYK (0.47) SMN1; SMN2SYKCTSKBACE1
SCHEMBL421286 0.76 SYK (0.61) SMN1; SMN2SYKLMNAAKT1CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3932909-B1 BENZOINDAZOLONE COMPOUND, AND INTERMEDIATE THEREOF LMITO THERAPEUTICS INC (KR) 2025-04-02 EP disclosed
US-12187683-B2 Benzoindazolone compound and intermediate thereof LMITO THERAPEUTICS INC. (KR) 2025-01-07 US disclosed
CN-113454068-B Benzonazolone compounds and intermediates thereof LMITO药业株式会社 2024-08-02 CN disclosed
US-20220144780-A1 BENZOINDAZOLONE COMPOUND AND INTERMEDIATE THEREOF LMITO THERAPEUTICS INC. (KR) 2022-05-12 US disclosed
CN-113454068-A Benzoindazolone compounds and intermediates thereof LMITO药业株式会社 2021-09-28 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12187683-B2 Benzoindazolone compound and intermediate thereof NQO1, KEAP1, SQOR SMN1; SMN2 2597/4885SYK 2078/4885LMNA 1476/4885
US-20220144780-A1 BENZOINDAZOLONE COMPOUND AND INTERMEDIATE THEREOF NQO1, KEAP1, SQOR SMN1; SMN2 2597/4885SYK 2078/4885LMNA 1476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.